Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MREO with free AI briefings, catalyst countdowns, and dilution alerts.

MREO · Mereo BioPharma Group plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$26.1M Cash on Hand
15.5mo Cash Runway
Follow MREO by email Get an email when MREO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MREO, unsubscribe in one click. Privacy

📣 What MREO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Setrusumab Osteogenesis Imperfecta Phase 2/3 · NCT05125809 Active not recruiting
BPS804 Osteogenesis Imperfecta Phase 2 · NCT03216486 Withdrawn
Alvelestat Hematologic Malignancy Phase 1/2 · NCT03986086 Withdrawn
Investigational new drug company code: BGS649 Obese Hypogonadotropic Hypogonadism Phase 2 · NCT01200862 Terminated
Etigilimab Ovarian Cancer Phase 2 · NCT05715216 Active not recruiting
Active treatment with a high dose of BGS649 Endometriosis Phase 2 · NCT01190475 Completed
Leflutrozole Hypogonadotropic Hypogonadism Phase 2 · NCT02908074 Completed
BCT197 Acute Kidney Injury Phase 2 · NCT01336959 Terminated
Alvelestat oral tablet - dose 2 Alpha 1-Antitrypsin Deficiency Phase 2 · NCT03636347 Completed
Alvelestat oral tablet - dose 1 Alpha 1-Antitrypsin Deficiency Phase 2 · NCT03636347 Completed

Also used in these trials (approved or third-party drugs, not MREO's own candidates): Zoledronic Acid, Prednisone, Nivolumab, Itraconazole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MREO holds $26.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $5M/quarter from operations, an estimated runway of 15.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MREO files for a raise →

👥 Who Owns MREO

Insiders 0.2% Institutions (63 holders) 33.6% Public and other holders 66.2%
HolderTypeShares% of sharesAs of
683 Capital Management, LLC Institution (13G, 5%+) 65,083,815 8.15% 2025-12-29
Denise Scots-Knight
Chief Executive Officer, Director · +1.65M options
Insider 808,921 0.10% 2024-09-12
Charles Sermon
General Counsel · +662,250 options
Insider 219,061 0.03% 2024-09-12
John A. Lewicki
Chief Scientific Officer · +307,637 options
Insider 92,826 0.01% 2024-09-12
Christine Ann Fox
Chief Financial Officer · +647,250 options
Insider 89,285 0.01% 2024-09-12
Alexandra Hughes-Wilson
Chief Patient Access and Commercial Plan · +410,250 options
Insider 50,475 0.01% 2024-09-12

Share count 798,503,184 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MREO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MREO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.